Nivalis Therapeutics Improves the Clinical Trial Experience for Patients and Investigators with an End-to-End Payment Solution

Nivalis Therapeutics is dedicated to the discovery and development of innovative solutions that improve and extend the lives of people with CF.

CASE STUDY

Cystic Fibrosis: Research to Find a CureCystic Fibrosis (CF) is a life-shortening genetic disease that affects an estimated 65,000 in the United States and Europe. The underlying mutation and the type and severity of CF symptoms can differ widely from person to person, so the treatment plan can vary. There is a dedicated effort around the world to advance the therapies to treat CF from many angles.

Nivalis Therapeutics is dedicated to the discovery and development of innovative solutions that improve and extend the lives of people with CF. The Company is developing a novel class of disease-modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects that may help address the pathophysiology of CF.

Nivalis has conducted two trials over the course of the last three years, working closely with more than 45 research sites, doctors and investigators who are caring for and working with the both patients and families living with CF.

Eliminating Hurdles and Distractions with a Comprehensive Solution Robert Hopkins, the Senior Director of Clinical Research at Nivalis, wanted to eliminate any hurdles and distractions at the organization that may limit the team’s ability to be laser-focused on one goal – delivering a better trial experience for investigators, patients and their families.

CF clinical trials, like many other rare disease studies, have an additional layer of sensitivity and complexity. As people with CF are born with the disease, patients, their families, care-givers and doctors share a strong bond from the time the child was born, working closely together to

Nivalis was able to automate and streamline the cash flow processes to its site partners as well as their patients and families.

determine the right course of treatment and therapies. As a result, many times the doctors and study staff at the trial sites are considered an extension of the patient’s family.

Recognizing the impact that administrative and office work has on a clinical trial investigators and coordinators, Nivalis embraces any opportunity to reduce the distractions and hurdles that often stand in the way of an investigator’s ability to successfully do their job. Additionally, Nivalis recognized a need to remove barriers to patient and family participation through using a solution that would provide immediate reimbursement for any travel costs incurred in order for patients to attend their study visits and receive treatment.

By implementing Greenphire’s eClinical GPS and ClinCard Travel Module solutions, Nivalis was able to automate and streamline the cash flow processes to its site partners as well as their patients and families. The ability to request and receive funds from Nivalis and reimburse the patients and their families for trial participation and travel expenses had a tremendous impact, while supporting an overall better clinical trial experience for all involved.

A close, trusting relationship with the research sites and investigators is engrained in the culture at Nivalis. By eliminating the headaches and frustrations for reimbursements and compensation, the Greenphire solutions clearly supported this effort.

For more than three years, the ClinCard solution has been leveraged by the Nivalis team to improve patient retention and participation. The solution eliminates any financial constraints on the patients, families and caretakers, which has improved study participation and created a better relationship between all parties involved.

Being a very small sponsor organization, the eClinicalGPS solution further improved the site and investigator’s relationship and satisfaction with Nivalis. As a small organization with limited resources, Nivalis needs solutions that simplify and automate tactical processes so the team can remain focused on innovation and therapy development.

The ClinCard and eClinicalGPS solutions uniquely fit the needs of Nivalis’ clinical trials, with a team that understands the sensitivity and complexities of the users and patients. Greenphire is the partner that clearly understands that when it comes to clinical trials, particularly in rare diseases, success is more than just getting money to the right people at the right time, it’s about delivering a superior trial experience for everyone involved.

Greenphire is the leader in global clinical trial payment solutions. Greenphire’s best-in-class solutions optimize clinical trial performance by simplifying and streamlining payment processes from sponsors and CROs to sites and patients. Greenphire’s ClinCard and eClinicalGPS solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials. Learn more at www.greenphire.com.